Prospective study evaluates ctDNA as a marker for minimal residual disease in aggressive B-cell lymphoma, suggesting its correlation with PET-CT metrics.
Key Points
ctDNA levels correlated significantly with total metabolic tumor volume (ρ = 0.91, p < 0.0001), indicating its potential as a biomarker.
Baseline ctDNA was detected in 79% of patients, reflecting its relevance for real-time monitoring of aggressive B-cell lymphoma.
Longitudinal monitoring of ctDNA revealed kinetics that mirrored PET-CT metabolic changes, highlighting its predictive value.
The study demonstrates the complementary potential of ctDNA-based monitoring alongside PET-CT for assessing treatment response.